BACKGROUND: High-sensitivity C-reactive protein (hs-CRP) is a sensitive systemic marker of inflammation, and increased levels of hs-CRP are associated with inflammatory reactions. Microglia-mediated neuroinflammation has been hypothesized to play an important role in the pathogenesis of idiopathic Parkinson's disease (PD). However, the clinical value of hs-CRP in PD is poorly defined. Therefore, we conducted this study to investigate the clinical value of hs-CRP in patients with PD. METHODS: We examined 212 patients with de novo PD, 253 patients with acute ischemic cerebrovascular disease and 119 healthy subjects and investigated the differences in hs-CRP among these 3 groups. The PD group was classified into 4 subgroups according to the Hoehn and Yahr stage to investigate the relationship between hs-CRP and symptom severity. RESULTS: There was no significant difference in the hs-CRP value between the PD and the ischemic cerebrovascular disease groups, but the subjects in the 2 disease groups demonstrated higher hs-CRP levels than those in the normal control group. A post-hoc analysis of the 4 PD subgroups showed no significant differences in hs-CRP values. In addition, this study demonstrated that the odds ratio of the PD group by hs-CRP was 2.037 (95% CI 1.180-3.517; p = 0.011). CONCLUSION: We suggest that our results could support the hypothesis that neuroinflammation contributed to the pathogenesis of PD and cautiously assume that elevated hs-CRP might have a clinical value as a risk factor for PD. Copyright 2009 S. Karger AG, Basel.
BACKGROUND: High-sensitivity C-reactive protein (hs-CRP) is a sensitive systemic marker of inflammation, and increased levels of hs-CRP are associated with inflammatory reactions. Microglia-mediated neuroinflammation has been hypothesized to play an important role in the pathogenesis of idiopathic Parkinson's disease (PD). However, the clinical value of hs-CRP in PD is poorly defined. Therefore, we conducted this study to investigate the clinical value of hs-CRP in patients with PD. METHODS: We examined 212 patients with de novo PD, 253 patients with acute ischemic cerebrovascular disease and 119 healthy subjects and investigated the differences in hs-CRP among these 3 groups. The PD group was classified into 4 subgroups according to the Hoehn and Yahr stage to investigate the relationship between hs-CRP and symptom severity. RESULTS: There was no significant difference in the hs-CRP value between the PD and the ischemic cerebrovascular disease groups, but the subjects in the 2 disease groups demonstrated higher hs-CRP levels than those in the normal control group. A post-hoc analysis of the 4 PD subgroups showed no significant differences in hs-CRP values. In addition, this study demonstrated that the odds ratio of the PD group by hs-CRP was 2.037 (95% CI 1.180-3.517; p = 0.011). CONCLUSION: We suggest that our results could support the hypothesis that neuroinflammation contributed to the pathogenesis of PD and cautiously assume that elevated hs-CRP might have a clinical value as a risk factor for PD. Copyright 2009 S. Karger AG, Basel.
Authors: Thanh G N Ton; Samay Jain; Mary L Biggs; Evan L Thacker; Elsa S Strotmeyer; Robert Boudreau; Anne B Newman; W T Longstreth; Harvey Checkoway Journal: Parkinsonism Relat Disord Date: 2011-11-26 Impact factor: 4.891
Authors: Medha Priyadarshini; Mohammad A Kamal; Nigel H Greig; Marcella Reale; Adel M Abuzenadah; Adeel G A Chaudhary; Ghazi A Damanhouri Journal: CNS Neurol Disord Drug Targets Date: 2012-06-01 Impact factor: 4.388
Authors: Mike A Nalls; Mohamad Saad; Alastair J Noyce; Margaux F Keller; Anette Schrag; Jonathan P Bestwick; Bryan J Traynor; J Raphael Gibbs; Dena G Hernandez; Mark R Cookson; Huw R Morris; Nigel Williams; Thomas Gasser; Peter Heutink; Nick Wood; John Hardy; Maria Martinez; Andrew B Singleton Journal: Hum Mol Genet Date: 2013-09-20 Impact factor: 6.150
Authors: Jonathan Thévenet; Rosanna Pescini Gobert; Robertus Hooft van Huijsduijnen; Christoph Wiessner; Yves Jean Sagot Journal: PLoS One Date: 2011-06-27 Impact factor: 3.240